Eledon Pharmaceuticals, Inc. (ELDN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$2.70+3.05%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ELDN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
ELDN — earnings in line
Dated 2026-08-13
of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Why it matters: Eledon reported $88.8 million in cash and short-term investments at June 30. Its planned trials need funding, so the next cash update matters.
Worry ifAt its next cash update, Eledon reports less than $44 million in cash and short-term investments. Or it moves its runway estimate to before Q2 2027.
Less concerning ifEledon reports at least $44 million in cash and short-term investments and keeps its runway estimate at or beyond Q2 2027.
Why it matters: Earlier kidney data favored tegoprubart. The planned Phase 3 trial tests if it can match tacrolimus on rejection, graft loss, and death.
Watch forThe trial meets its 52-week non-inferiority goal for the combined measure of rejection, graft loss, and death.
Also watch forThe trial fails to meet its 52-week non-inferiority goal for that combined measure.
Why it matters: The trial is Eledon's top stated goal. Starting it on time would move tegoprubart into a large test against current care.
Supportive ifBy December 31, 2026, Eledon says the trial has started. Patients are enrolling toward its planned 600-person target.
Worry ifEledon reports the trial has not started by December 31, 2026, or says the start is delayed beyond late 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$188 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $702 loss on $10,000 · 7.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,659 loss on $10,000 · 66.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.